Home > Food, Nutrition & Animal Feed > Chondroitin Market
Chondroitin Market size is projected to experience a healthy growth during 2023 to 2032, due to rising application scope in the cosmetic and pharmaceutical sectors.
Chondroitin primarily refers to a molecule that occurs naturally in the connective tissues of animals and people, providing a building block for producing new cartilage in the body. Commercial chondroitin is derived from natural sources, such as bovine and shark cartilage, as well as through synthetic production. Thus, the increasing adoption in dietary supplements to limit cartilage breakdown while stimulating repair mechanisms will influence the market demand.
The growth of the chondroitin market can further be attributed to the surging burden of osteoarthritis, mainly amongst the elderly population, making way for the rising number of clinical studies. As per PLOS, osteoarthritis affects 10% of the worldwide population base aged 60 years and above. This expanding osteoarthritis patient pool is expected to drive chondroitin demand for improving the cartilage health by absorbing fluids into the connective tissue.
The onset of the COVID-19 pandemic also gave a boost to the market trends in the pharmaceutical sector with the emergence of AVN (Avascular Necrosis), one of the major post-COVID complications affecting the thigh bones and hip joints of the recovered patients. However, the ongoing Russia-Ukraine war and its ramifications will negatively sway the product penetration on account of the disrupted supply chain and manufacturing operations, leading to hampered import and exports.
With respect to end-use, the chondroitin market share from the cardiovascular health segment will expand exponentially through 2032, driven by the robust utilization of chondroitin and glucosamine supplements in limiting the risks of coronary heart diseases, strokes, and CVD-related deaths. As per the CDC (Centers for Disease Control and Prevention), over 795,000 people in the U.S. have a stroke every year. Furthermore, the growing threat of cardiovascular ailments worldwide will open new growth avenues for several chondroitin brands, resulting in enhanced industry application outlook.
Latin America will record significant revenue increases for the chondroitin market between 2023 and 2032, ascribing to the higher prevalence of chronic disorders, including obesity. Factors, such as the changing consumer lifestyles and excessive smoking, have led to the surging prevalence of rheumatic disorders, such as arthritis, mainly in Brazil. As per a recent report by National Center For Biotechnology Information, chronic diseases are responsible for nearly 928,000 deaths per year in Brazil. Hence, the rising adoption of chondroitin in supplements will anchor the regional market growth.
Some of the leading companies involved in the chondroitin market include Nippon Zoki, Sioux Pharm, Synutra International, TSI Group, and Pacific Rainbow. Innovative product launches, capacity expansions, as well as strategic mergers and acquisitions are the leading initiatives employed by these industry contenders to gain competitive benefits. To cite an instance, Bioiberica, in May 2021, collaborated with Apsen to introduce Motilex HA, a new mobility product in Brazil. The new system comprises Bioiberica’s Mobilee and is integrated with b-2Cool ingredients among other key joint health ingredients, such as chondroitin sulphate.
In the coming years, the rising burden of cataracts will positively push the demand for chondroitin sulfate emulsions for effectively reducing the symptoms of dry eye diseases. The rising popularity of chondroitin sulfate for relieving arthritis pain by imparting anti-inflammatory properties is another impact rendering factor driving the industry growth.